

Sadakatsu Ikeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7961157/publications.pdf>

Version: 2024-02-01

33
papers

1,264
citations

623734

14
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

2396
citing authors

#	ARTICLE	IF	CITATIONS
1	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. <i>Molecular Cancer</i> , 2017, 16, 149.	19.2	338
2	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19,784 Diverse Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 1565.	7.1	195
3	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. <i>Npj Genomic Medicine</i> , 2016, 1, .	3.8	103
4	Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. <i>Cancer Research</i> , 2017, 77, 5419-5427.	0.9	92
5	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	7.0	54
6	Molecular landscape of prostate cancer: Implications for current clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 761-766.	7.7	53
7	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2553-2562.	4.1	50
8	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	2.2	49
9	Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1114-1122.	4.1	47
10	MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 76.	17.0	42
11	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Oncolmmunology</i> , 2020, 9, 1708065.	4.6	41
12	The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 297-305.	4.1	34
13	Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. <i>Cancer Biology and Therapy</i> , 2019, 20, 219-226.	3.4	30
14	Multiplex gene panel testing for lung cancer patients. <i>Pathology International</i> , 2020, 70, 921-931.	1.3	29
15	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 699-706.	7.7	14
16	Estimating copy number using next-generation sequencing to determine ERBB2 amplification status. <i>Medical Oncology</i> , 2021, 38, 36.	2.5	14
17	Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. <i>PLoS ONE</i> , 2022, 17, e0266112.	2.5	13
18	JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. <i>JAMA Dermatology</i> , 2017, 153, 449.	4.1	10

#	ARTICLE	IF	CITATIONS
19	<i>KRAS</i> -Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. <i>Oncologist</i> , 2021, 26, e530-e536.	3.7	9
20	A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). <i>Annals of Surgical Oncology</i> , 2021, 28, 8497-8505.	1.5	8
21	Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers. <i>Current Oncology</i> , 2021, 28, 3717-3728.	2.2	8
22	Primary pulmonary choriocarcinoma with a genomic sequence. <i>Pathology International</i> , 2022, 72, 141-143.	1.3	6
23	First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. <i>Cancer</i> , 2022, , .	4.1	6
24	Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS6094-TPS6094.	1.6	5
25	METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 361-370.	0.1	3
26	ASO Author Reflections: Impact of Liquid Biopsy Using Plasma Cell-Free DNA in Solid Tumors in Japan. <i>Annals of Surgical Oncology</i> , 2021, 28, 8506-8507.	1.5	2
27	Basaloid Squamous Cell Carcinoma of the Uterine Cervix: Report of a Case With Molecular Analysis. <i>International Journal of Surgical Pathology</i> , 2021, 29, 770-774.	0.8	2
28	Treatment of advanced lung cancer based on genomic profiling using liquid biopsy (plasma): A review of three cases. <i>Thoracic Cancer</i> , 2021, 12, 2508-2512.	1.9	2
29	A Case Report of a Non-small-cell Lung Cancer Patient Who Was EGFR-negative on a Conventional Test but Was Discovered to Have an <i>EGFR</i> Uncommon Mutation on Comprehensive Genomic Profiling and Responded to Afatinib. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 429-433.	0.1	2
30	MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 124, 105666.	1.5	2
31	Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3131-3131.	1.6	1
32	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among <i>MET</i> amps in diverse advanced cancer types.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3046-3046.	1.6	0
33	The clinical utility of comprehensive genomic profiling for recurrent / metastatic head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2021, 47, 359-365.	0.1	0